ENDPOINTS

NIH payment cuts are 'reasoned and rational,' governmen...

The federal government said it "ran afoul of no statute" when it announced a 15%...

Novo looks to recoup $830M from hypertension drug partner

A judge in Singapore ordered the freezing of KBP Biosciences’ assets while Novo ...

Siegfried’s stock slips over dampened sales outlook for...

Siegfried’s stock dipped by 6% on the Swiss stock exchange Tuesday after reporti...

What federal job cuts at HHS mean for health tech

Shortly after Robert F. Kennedy Jr. was confirmed as HHS secretary, the White Ho...

In turnaround, Solid Bio reports promising initial data...

Solid Biosciences reported that three children with Duchenne muscular dystrophy ...

Arcus touts early kidney cancer data as Gilead declines...

Arcus Biosciences presented new Phase 1/1b data for a kidney cancer program over...

Septerna ends Phase 1 trial for hypoparathyroidism drug...

Plus, news about Basilea, TME Pharma and Perceive Biotherapeutics: Septerna ...

After research pivot, Biogen beefs up pipeline with Sto...

A month after Biogen signaled plans to shift its attention to "external opportun...

Hikma takes Amarin's 'skinny label' fight to the Suprem...

Hikma Pharmaceuticals is asking the US Supreme Court to review a generic drug la...

Bavarian Nordic wins FDA OK for chikungunya vaccine in ...

The FDA has approved Bavarian Nordic’s chikungunya vaccine for adolescents and a...

Subsense launches with $17M to build a noninvasive brai...

Subsense, a startup building noninvasive technology to communicate with the brai...

Algo’s topical pain treatment fails Phase 2 study with ...

AlgoTherapeutix’s topical non-opioid drug has flunked a mid-stage trial in chemo...

Exclusive: Lithuanian biotech Atrandi Biosciences raise...

A biotech based in Vilnius, Lithuania has won the backing of Lux Capital as the ...

Exclusive: AI biotech Atomwise hires new CEO, raises $4...

Atomwise spent most of its first 12 years talking up the potential of AI in maki...

FDA approves Ono’s rare joint tumor drug, setting up ba...

The FDA approval of Romvimza in a rare cancer means Ono Pharmaceutical has a fig...

Pain biotech Latigo eyes up to $150M raise following Ve...

Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves crea...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.